FROM THE EDITORS
Welcome to the HR+ HER2- Breast Cancer Resource Center! We’re excited to present you with current information, news items, highlights from the literature, and other resources that focus on this disease space and the advanced practitioner’s role in delivering high-quality care to patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.
![]() |
![]() |
Katie Newlin, RN, MSN, AGPCNP-BC Washington University in St. Louis/Siteman Cancer Center
|
Kate Taucher, PharmD, MHA, BCOP, FASHP, FAPO, FHOPA UCHealth Memorial Hospital |
Resources
Oral Chemotherapy Education
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)
Real-world Risk of Recurrence by Nodal Status in Patients with HR+, HER2-, Node-positive, High-Risk Early Breast Cancer
Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path
Ribociclib Plus Endocrine Therapy in Early Breast Cancer
News & Literature Highlights